Administration of Chlorpromazine as a Treatment for COVID-19

• Status: Not yet recruiting
• Trial end date: 2020-11-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study, defined cases of COVID-19 confirmed with PCR, with a mild, moderate or severe pneumonia will be treated with chlorpromazine. The improvement in clinical & laboratory manifestations will be evaluated in treated patient compared to control group.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Collaborator: Noha Mahmoud Nasreldin Hassan
• Treatments: Chlorpromazine

Criteria

Inclusion Criteria:

1. Adult conscious male and female (non-pregnant, non-breast feeder), level of consciousness is assessed by Glasgow Coma Scale ≥ 13.

2. Diagnosed initially with COVID-19 confirmed with PCR prior to any interference.

3. Follow the treatment regimen for COVID-19 according to The Ministry of Health in Egypt.

Exclusion criteria:

4. Patients having allergy to chlorpromazine which will be assessed by asking the patient or relative.

5. Patients with hypotension(<90/60mmHg).

6. Pregnant and breast feeder female patients.

7. Hepatic patients.

8. Patients already receiving chlorpromazine.